1-17 of 17
Paul Haluska
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Roisin M. Connolly, Eric Laille, Ulka Vaishampayan, Vincent Chung, Karen Kelly, Afshin Dowlati, Olatunji B. Alese, R. Donald Harvey, Paul Haluska, Lillian L. Siu, Shivaani Kummar, Richard Piekarz, S. Percy Ivy, Nicole M. Anders, Melinda Downs, Ashley O'Connor, Angela Scardina, Jacqueline Saunders, Gary L. Rosner, Michael A. Carducci, Michelle A. Rudek
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5329–5337.
https://doi.org/10.1158/1078-0432.CCR-20-1412
Published: 15 October 2020
View articletitled, Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study
Open the PDF for Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study in another window
Journal Articles

Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Aline Talhouk, Joshy George, Chen Wang, Timothy Budden, Tuan Zea Tan, Derek S. Chiu, Stefan Kommoss, Huei San Leong, Stephanie Chen, Maria P. Intermaggio, Blake Gilks, Tayyebeh M. Nazeran, Mila Volchek, Wafaa Elatre, Rex C. Bentley, Janine Senz, Amy Lum, Veronica Chow, Hanwei Sudderuddin, Robertson Mackenzie, Samuel C.Y. Leong, Geyi Liu, Dustin Johnson, Billy Chen, AOCS Group, Jennifer Alsop, Susana N. Banerjee, Sabine Behrens, Clara Bodelon, Alison H. Brand, Louise Brinton, Michael E. Carney, Yoke-Eng Chiew, Kara L. Cushing-Haugen, Cezary Cybulski, Darren Ennis, Sian Fereday, Renée T. Fortner, Jesús García-Donas, Aleksandra Gentry-Maharaj, Rosalind Glasspool, Teodora Goranova, Casey S. Greene, Paul Haluska, Holly R. Harris, Joy Hendley, Brenda Y. Hernandez, Esther Herpel, Mercedes Jimenez-Linan, Chloe Karpinskyj, Scott H. Kaufmann, Gary L. Keeney, Catherine J. Kennedy, Martin Köbel, Jennifer M. Koziak, Melissa C. Larson, Jenny Lester, Liz-Anne Lewsley, Jolanta Lissowska, Jan Lubiński, Hugh Luk, Geoff Macintyre, Sven Mahner, Iain A. McNeish, Janusz Menkiszak, Nikilyn Nevins, Ana Osorio, Oleg Oszurek, José Palacios, Samantha Hinsley, Celeste L. Pearce, Malcolm C. Pike, Anna M. Piskorz, Isabelle Ray-Coquard, Valerie Rhenius, Cristina Rodriguez-Antona, Raghwa Sharma, Mark E. Sherman, Dilrini De Silva, Naveena Singh, Peter Sinn, Dennis Slamon, Honglin Song, Helen Steed, Euan A. Stronach, Pamela J. Thompson, Aleksandra Tołoczko, Britton Trabert, Nadia Traficante, Chiu-Chen Tseng, Martin Widschwendter, Lynne R. Wilkens, Stacey J. Winham, Boris Winterhoff, Alicia Beeghly-Fadiel, Javier Benitez, Andrew Berchuck, James D. Brenton, Robert Brown, Jenny Chang-Claude, Georgia Chenevix-Trench, Anna deFazio, Peter A. Fasching, María J. García, Simon A. Gayther, Marc T. Goodman, Jacek Gronwald, Michelle J. Henderson, Beth Y. Karlan, Linda E. Kelemen, Usha Menon, Sandra Orsulic, Paul D.P. Pharoah, Nicolas Wentzensen, Anna H. Wu, Joellen M. Schildkraut, Mary Anne Rossing, Gottfried E. Konecny, David G. Huntsman, Ruby Yun-Ju Huang, Ellen L. Goode, Susan J. Ramus, Jennifer A. Doherty, David D. Bowtell, Michael S. Anglesio
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5411–5423.
https://doi.org/10.1158/1078-0432.CCR-20-0103
Published: 15 October 2020
View articletitled, Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Open the PDF for Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE) in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

Andrea E. Wahner Hendrickson, Michael E. Menefee, Lynn C. Hartmann, Harry J. Long, Donald W. Northfelt, Joel M. Reid, Felix Boakye-Agyeman, Olumide Kayode, Karen S. Flatten, Maria I. Harrell, Elizabeth M. Swisher, Guy G. Poirier, Daniel Satele, Jake Allred, Janet L. Lensing, Alice Chen, Jiuping Ji, Yiping Zang, Charles Erlichman, Paul Haluska, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (4): 744–752.
https://doi.org/10.1158/1078-0432.CCR-17-1590
Published: 01 February 2018
View articletitled, A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors
Open the PDF for A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens

Courtney L. Andersen, Matthew J. Sikora, Michelle M. Boisen, Tianzhou Ma, Alec Christie, George Tseng, Yongseok Park, Soumya Luthra, Uma Chandran, Paul Haluska, Gina M. Mantia-Smaldone, Kunle Odunsi, Karen McLean, Adrian V. Lee, Esther Elishaev, Robert P. Edwards, Steffi Oesterreich
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (14): 3802–3812.
https://doi.org/10.1158/1078-0432.CCR-16-1501
Published: 13 July 2017
View articletitled, Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens
Open the PDF for Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer

Amita Patnaik, Paul Haluska, Anthony W. Tolcher, Charles Erlichman, Kyriakos P. Papadopoulos, Janet L. Lensing, Muralidhar Beeram, Julian R. Molina, Drew W. Rasco, Rebecca R. Arcos, Claudia S. Kelly, Sameera R. Wijayawardana, Xuekui Zhang, Louis F. Stancato, Robert Bell, Peipei Shi, Palaniappan Kulanthaivel, Celine Pitou, Lynette B. Mulle, Daphne L. Farrington, Edward M. Chan, Matthew P. Goetz
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (5): 1095–1102.
https://doi.org/10.1158/1078-0432.CCR-15-1718
Published: 29 February 2016
View articletitled, A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer
Open the PDF for A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models.

Caroline C. Nitschmann, Rachel M. Hurley, Marc A. Becker, Xiaonan Hou, Ute Hoch, Thomas C. Harding, Deborah H. Charych, Scott H. Kaufmann, Paul Haluska, Saravut J. Weroha
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): B50.
https://doi.org/10.1158/1557-3265.OVCA15-B50
Published: 15 January 2016
View articletitled, Abstract B50: Antineoplastic activity of Top I inhibitor etirinotecan pegol (NKTR-102) and PARP inhibitor rucaparib (CO-388) in platinum-resistant high-grade serous BRCA WT ovarian cancer PDX models.
Journal Articles

Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy

William J. Gradishar, Denise A. Yardley, Rachel Layman, Joseph A. Sparano, Ellen Chuang, Donald W. Northfelt, Gary N. Schwartz, Hagop Youssoufian, Shande Tang, Ruslan Novosiadly, Amelie Forest, Tuan S. Nguyen, Jan Cosaert, Dmitri Grebennik, Paul Haluska
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 301–309.
https://doi.org/10.1158/1078-0432.CCR-15-0588
Published: 14 January 2016
View articletitled, Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Open the PDF for Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy in another window
Includes: Supplementary data
Journal Articles

Abstract 13: Individualized approach for ovarian cancer: Identification of potential therapeutic targets based on genomic analyses, testing efficiency of treatments, and monitoring

Faye R. Harris, Geoffrey C. Halling, Marc A. Becker, Paul Haluska, Jr., George Vasmatzis, Irina V. Kovtun
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (1_Supplement): 13.
https://doi.org/10.1158/1557-3265.PMSCLINGEN15-13
Published: 03 January 2016
View articletitled, Abstract 13: Individualized approach for ovarian cancer: Identification of potential therapeutic targets based on genomic analyses, testing efficiency of treatments, and monitoring
Journal Articles

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Angela DeMichele, Douglas Yee, Donald A. Berry, Kathy S. Albain, Christopher C. Benz, Judy Boughey, Meredith Buxton, Stephen K. Chia, Amy J. Chien, Stephen Y. Chui, Amy Clark, Kirsten Edmiston, Anthony D. Elias, Andres Forero-Torres, Tufia C. Haddad, Barbara Haley, Paul Haluska, Nola M. Hylton, Claudine Isaacs, Henry Kaplan, Larissa Korde, Brian Leyland-Jones, Minetta C. Liu, Michelle Melisko, Susan E. Minton, Stacy L. Moulder, Rita Nanda, Olufunmilayo I. Olopade, Melissa Paoloni, John W. Park, Barbara A. Parker, Jane Perlmutter, Emanuel F. Petricoin, Hope Rugo, Fraser Symmans, Debasish Tripathy, Laura J. van‘t Veer, Rebecca K. Viscusi, Anne Wallace, Denise Wolf, Christina Yau, Laura J. Esserman
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (13): 2911–2915.
https://doi.org/10.1158/1078-0432.CCR-14-1760
Published: 30 June 2015
View articletitled, The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
Open the PDF for The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer in another window
Journal Articles

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Andres Forero-Torres, Katherine E. Varley, Vandana G. Abramson, Yufeng Li, Christos Vaklavas, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna M. Storniolo, Tiffany A. Traina, Sujata Patil, Catherine H. Van Poznak, Julie R. Nangia, William J. Irvin, Jr, Helen Krontiras, Jennifer F. De Los Santos, Paul Haluska, William Grizzle, Richard M. Myers, Antonio C. Wolff
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2722–2729.
https://doi.org/10.1158/1078-0432.CCR-14-2780
Published: 14 June 2015
View articletitled, TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Open the PDF for TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

Paul Haluska, Michael Menefee, Elizabeth R. Plimack, Jonathan Rosenberg, Donald Northfelt, Theresa LaVallee, Li Shi, Xiang-Qing Yu, Patricia Burke, Jaiqi Huang, Jaye Viner, Jennifer McDevitt, Patricia LoRusso
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (18): 4747–4757.
https://doi.org/10.1158/1078-0432.CCR-14-0114
Published: 14 September 2014
View articletitled, Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors
Open the PDF for Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer

Mariam Al Hilli, S. John Weroha, Marc Becker, Xiaonan Hou, Sean Harrington, Sarah McKinstrey, Kimberly Kalli, Karin Goodman, Keith Wilcoxen, Elizabeth Swisher, Scott Kaufmann, Paul Haluska
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19_Supplement): PR05.
https://doi.org/10.1158/1078-0432.OVCA13-PR05
Published: 13 May 2014
View articletitled, Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer
Journal Articles

Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer

S. John Weroha, Marc A. Becker, Sergio Enderica-Gonzalez, Sean C. Harrington, Ann L. Oberg, Matthew J. Maurer, Sarah E. Perkins, Mariam AlHilli, Kristina A. Butler, Sarah McKinstry, Stephanie Fink, Robert B. Jenkins, Xiaonan Hou, Kimberly R. Kalli, Karin M. Goodman, Jann N. Sarkaria, Beth Y. Karlan, Amanika Kumar, Scott H. Kaufmann, Lynn C. Hartmann, Paul Haluska
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (5): 1288–1297.
https://doi.org/10.1158/1078-0432.CCR-13-2611
Published: 02 March 2014
View articletitled, Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer
Open the PDF for Tumorgrafts as In Vivo Surrogates for Women with Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials

Angela DeMichele, Donald A. Berry, JoAnne Zujewski, Sally Hunsberger, Larry Rubinstein, Joseph E. Tomaszewski, Gary Kelloff, Jane Perlmutter, Meredith Buxton, Julia Lyandres, Kathy S. Albain, Chris Benz, A. Jo Chien, Paul Haluska, Brian Leyland-Jones, Minetta C. Liu, Pamela Munster, Olufunmilayo Olopade, John W. Park, Barbara A. Parker, Lajos Pusztai, Debu Tripathy, Hope Rugo, Douglas Yee, Laura Esserman
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 2817–2823.
https://doi.org/10.1158/1078-0432.CCR-12-2620
Published: 30 May 2013
View articletitled, Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
Open the PDF for Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials in another window
Journal Articles

IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors

Marc A. Becker, Xiaonan Hou, Sean C. Harrington, S. John Weroha, Sergio E. Gonzalez, Kristina A. Jacob, Joan M. Carboni, Marco M. Gottardis, Paul Haluska
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1808–1817.
https://doi.org/10.1158/1078-0432.CCR-11-1806
Published: 14 March 2012
View articletitled, IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors
Open the PDF for IGFBP Ratio Confers Resistance to IGF Targeting and Correlates with Increased Invasion and Poor Outcome in Breast Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors

Paul Haluska, Heather M. Shaw, Gretchen N. Batzel, Donghua Yin, Julian R. Molina, L. Rhoda Molife, Timothy A. Yap, M. Luisa Roberts, Amarnath Sharma, Antonio Gualberto, Alex A. Adjei, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5834–5840.
https://doi.org/10.1158/1078-0432.CCR-07-1118
Published: 01 October 2007
View articletitled, Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors
Open the PDF for Phase I Dose Escalation Study of the Anti–Insulin-Like Growth Factor-I Receptor Monoclonal Antibody CP-751,871 in Patients with Refractory Solid Tumors in another window
Journal Articles

Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor

Johann S. de Bono, Gerhardt Attard, Alex Adjei, Michael N. Pollak, Peter C. Fong, Paul Haluska, Luisa Roberts, Carrie Melvin, Madeline Repollet, David Chianese, Mark Connely, Leon W.M.M. Terstappen, Antonio Gualberto
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (12): 3611–3616.
https://doi.org/10.1158/1078-0432.CCR-07-0268
Published: 15 June 2007
View articletitled, Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor
Open the PDF for Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor in another window